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ABSTRACT 
Some of the most promising novel tuberculosis (TB) vaccine strategies currently 
under development are based on respiratory vaccination, mimicking the natural 
route of infection. In this work, we have compared pulmonary and subcutaneous 
BCG immunization in the TB susceptible DBA/2 mouse strain, a model in which 
parenteral BCG does not protect. Our data show that intranasal but not 
subcutaneous BCG confers robust protection against pulmonary TB challenge. In 
addition, our results indicate that pulmonary vaccination triggers a TB-specific 
mucosal immune response orchestrated by IL17A. Thus, IL17A neutralization in 
vivo reduces protection, as well as it abrogates TB-specific IgA secretion to 
respiratory airways and lung expression of pIgR induced following intranasal 
vaccination. Altogether, our results demonstrate that pulmonary BCG vaccination 
can overcome lack of protection observed when BCG is given by parenteral route, 
suggesting that respiratory TB vaccines could have an advantage in TB endemic 
countries, where intradermal BCG results inefficient against pulmonary TB. 
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BACKGROUND 
Tuberculosis (TB) disease causes one and a half million deaths per year, and is one 
of the leading infectious diseases affecting mainly developing and underdeveloped 
countries. The rising spread of multidrug resistant strains with the increasing 
globalization makes TB an alarming global health problem [1]. Therefore, there is 
an urgent need for new effective TB vaccines. 
The only vaccine against TB in use today, the Bacille Calmette-Guerin (BCG), is a 
live attenuated strain of Mycobacterium bovis. BCG was initially designed as an oral 
vaccine, but since the 1970s intradermal administration at birth was established 
worldwide. Nowadays, BCG is considered effective in reducing the rate of severe 
forms of TB (meningitis and miliary TB) in children, but is inconsistent in 
preventing spread of pulmonary TB responsible of disease transmission [2]. 
Vaccination through the natural route of infection represents an attractive 
approach in vaccinology for priming the natural host immunity. In the case of TB, 
pulmonary mucosal tissue is the primary site for establishment of infection. 
Nevertheless, it is unclear which are the primary defence mechanisms of the 
mucosal immune response triggered during early TB infection. IL17A has emerged 
as a key molecule in the induction and maintenance of mucosal immunity [3-5]. 
Although this cytokine was initially described to participate in the elimination of 
extracellular pathogens and fungi [6, 7] due to its neutrophil recruitment capacity 
[8], it can also contribute to protection against intracellular bacteria [9, 10]. 
Results obtained with IL17A-knockout mice reveal no greater sensitivity to 
Mycobacterium tuberculosis (MTB) than wild-type mice in short-term TB challenge 
experiments [11]. However, a recent study has shown that this result depends on 
the virulence level of the MTB strain used for infection [12]. IL17A is known to 
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orchestrate the optimal organization of granuloma during TB infection in mice [13, 
14], which could explain the higher mortality rate of IL17RA-defficient mice in 
long-term TB infections [15]. Regarding the role of mucosal immunoglobulins (Ig) 
during mycobacterial infection, IgA-deficient mice are more sensitive to 
pulmonary challenge with BCG [16], suggesting a role for IgAs in mycobacterial 
infections. Mice knockout for the polymeric Ig receptor (pIgR), a protein expressed 
in the mucosal epithelium whose function is to translocate IgAs from lamina 
propria to the gut lumen or lung airways [17, 18], show greater susceptibility to TB 
challenge [19]. 
Depending on their sensitivity to TB infection, mouse strains have been classified 
into susceptible and non-susceptible [20]. Besides their different susceptibility 
profile to TB challenge, these strains also differ in the protective response 
following parenteral BCG vaccination. Whereas resistant strains C57/BL6 and 
BALB/c, the most used mouse models for TB vaccine comparison, show good 
vaccine-induced protection, parenteral immunization with BCG does not confer 
protective efficacy in susceptible strains CBA/J or DBA/2 [21, 22]. 
In this work, we carried out a comparative study of intranasal and subcutaneous 
BCG vaccination in the TB susceptible mouse strain DBA/2. Our data demonstrate 
that pulmonary BCG delivery overcomes lack of protection observed after 
subcutaneous vaccination in a process mediated by IL17A.  
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MATERIALS AND METHODS 
Bacteria 
Mycobacterial strains were grown at 37°C in Middlebrook 7H9 broth (BD 
Biosciences) supplemented with ADC (BD Biosciences) and 0.05% (v/v) Tween-
80, or on solid Middlebrook 7H11 (BD Biosciences) supplemented with ADC. 
Bacterial suspensions for vaccination or infection were prepared in PBS from 
glycerol stocks previously quantified. 
Mice 
All mice were kept under controlled conditions and observed for any sign of 
disease. Experimental work was conducted in agreement with European and 
national directives for protection of experimental animals and with approval from 
the competent local ethics committees.  
For protection studies, groups of eight week-old female C57/BL6 or DBA/2JRj 
mice (Janvier Biolabs) were vaccinated subcutaneously (100 l) or intranasally 
(40 l) with 106 CFU of BCG Danish 1331 in PBS. Eight weeks post-vaccination, 
mice were intranasally challenged with 100 CFU (low-dose challenge) or 1000 CFU 
(high-dose challenge) of MTB H37Rv in 40 l of PBS. Bacterial load from 
homogenized lungs and spleen was determined four weeks post-challenge by 
plating on solid medium. For survival experiments, disease-associated symptoms 
(including weight, aspect and individual/social behaviour) were monitored 
weekly, and mice were humanely euthanized according to pre-established 
endpoint criteria. Histological studies were performed according to a previous 
work [23]. 
For immunogenicity studies, eight week-old female DBA/2JRj mice were 
vaccinated subcutaneously or intranasally with 106 CFU of BCG Danish 1331 in 
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PBS. At the indicated time points, animals were euthanized and splenocytes and 
lung cells collected and stimulated with Purified Protein Derivative (PPD) (Statens 
Serum Institute, SSI) 5 g/ml overnight for intracellular staining (ICS), or during 
48 hours for supernatants collection and cytokine detection by ELISA. For 
bronchoalveolar lavage (BAL) collection, trachea was cannulated and BAL was 
performed with 0.8 ml of ice-cold PBS. Supernatant was separated from cells by 
centrifugation and frozen at -80ºC for further IgA detection analysis. 
IL17A neutralization in vivo 
IL17A neutralization was performed as described previously [24]. Briefly, mice 
were inoculated intraperitoneally with 500 g of antiIL17A clone 17F3 (BioXcell) 
or isotype control in 100 µl of PBS the day before vaccination and twice a week 
thereafter until experiment completion. 
Flow cytometry  
For intracellular staining (ICS), GolgiPlug (BD Biosciences) was added to cells 
during the last six hours of incubation with PPD. Then, cells were fixed and 
permeabilized with the Cytofix/Cytoperm Fixation/Permeabilization Kit (BD 
Biosciences) following manufacturer instructions. Cells were stained with 
antiIL17A-APC.Cy7 and antiIFN-APC (BD Biosciences). For surface staining, cells 
were labelled with antiCD4-FITC, antiCD8-PE, antiLy6G-Pacific Blue, CD11b-PE 
(BD Biosciences) or CD11c-FITC (Miltenyi Biotec) diluted in culture medium with 
10% FCS. Cells were acquired with a Gallios Flow Cytometer (Beckman). 
ELISA 
Cytokine concentration in supernatants was determined by using mouse IL17A or 
IFN specific ELISA kits (MabTECH). 
7 
For IgAs determination in BAL, maxisorp ELISA plates (NUNC) were coated with 
BAL (for total IgA) or 10 g/ml of H37Rv sonicate (for MTB-specific IgA) and 
incubated overnight at 4ºC. After a washing step with PBS-Tween20 0.05% (v/v) 
buffer, plate was blocked with Bovine Serum Albumin 1% (w/v) in washing buffer 
for 1 hour at 37ºC. Then, MTB sonicate-coated plates were incubated with 200 l 
of BAL during 90 minutes at 37ºC. Following washing, plates were incubated for 1 
hour at 37ºC with Horseradish Peroxidase (HRP)-conjugated goat anti-mouse IgA 
diluted 1:10000 (Sigma). Finally, enzyme-substrate reaction was developed using 
3,3′,5,5′-Tetramethylbenzidine (TMB) (Sigma) as substrate, and reaction was 
stopped with H2SO4 0.1N. Standard curve to calculate IgA concentration was 
performed using a mouse reference serum (Bethyl technologies). Optical density 
was measured at 450 nm. 
Western-Blot 
Lung protein lysates were prepared by adding 100 l of RIPA buffer (2x 
concentrated) to 100 l of homogenised lung followed by boiling at 100ºC for 1 
hour. Then, supernatant was separated by centrifugation at 14000 x g for 15 
minutes, and protein concentration measured with the QuantiPro BCA Assay kit 
(Sigma). Ten micrograms of protein per well were loaded and separated by SDS-
PAGE. Immunodetection was carried out using a polyclonal goat anti-pIgR (R&D 
systems). Then, membranes were incubated with HRP-conjugated anti goat IgG 
secondary antibody (Sigma) and developed with ECL Plus Western Blotting System 
(GE HealthCare). Band intensities were calculated with the ImageJ software. 
Statistical Analysis 
GraphPrism software was used for statistical analysis. For experiments with two 
experimental groups, unpaired t-student test was used. When three or more 
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groups were compared, One-Way ANOVA analysis with Bonferroni post-test was 
performed. Differences were considered significant at p<0.05. 
 
RESULTS 
Intranasal but not subcutaneous BCG vaccination confers protection to 
DBA/2 against Mycobacterium tuberculosis challenge 
Previous data indicated that subcutaneous vaccination with BCG does not protect 
against TB in the susceptible mouse strain DBA/2 [21, 22]. To confirm these data 
under our experimental conditions, groups of C57/BL6 and DBA/2 mice were 
subcutaneously vaccinated with BCG Danish and after intranasal challenge with a 
low dose of H37Rv, we measured bacterial burden in lungs four weeks later. 
Vaccinated C57/BL6 animals showed one-log reduction as compared to non-
vaccinated group (Figure 1A), whereas no difference was observed between both 
vaccinated and unvaccinated DBA/2 mice (Figure 1B). 
Recently, we reported that pulmonary BCG is more effective than subcutaneous 
vaccination in C57/BL6 mice [25]. As a result we considered extending these 
studies to DBA/2 mice in a short-term protection design to explore whether 
vaccination by the natural route of infection could protect against TB in a model 
where parenteral BCG immunization fails. After low dose H37Rv challenge, 
intranasal BCG reduced bacterial burden in lungs by about two logs (Figure 2A) 
and approximately by one log after high dose challenge, as compared to 
unvaccinated or subcutaneous group (Figure 2B). Comparable results were 
obtained in spleen.  
To test whether this considerable bacterial load reduction by intranasal 
vaccination could be translated into increased survival and reduced disease, we 
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conducted a long-term survival study comparing subcutaneous and intranasal 
vaccination following high dose H37Rv challenge. Concordant with lung-bacterial 
load data in the short-term protection study, intranasal vaccination significantly 
increased mouse survival with a median of around four months post-challenge, 
whereas median survival of subcutaneous and non-vaccinated animals was about 
one month (Figure 2C). Altogether, these results indicate that intranasal BCG 
delivery overcomes lack of protective efficacy by subcutaneous route in DBA/2 
mice. 
Additionally, we explored whether BCG intranasal immunization could induce lung 
damage in this mouse model. Tissue damage caused by exacerbated inflammation 
is probably the main concern for the use of live TB vaccines by the pulmonary 
immunization route in humans. Our results revealed the presence of some 
histopathological findings in the lungs from animals vaccinated intranasally. We 
detected the presence of discrete inflammatory aggregates in a small proportion of 
lung tissue and mainly surrounding blood vessels. These findings were not found 
when animals were vaccinated subcutaneously (Supplementary Figure 1). 
Intranasal BCG vaccination induces IL17A production  
Th17 response has been shown to correlate with vaccine-induced protection in 
preclinical animal models [26]. Given the protective efficacy obtained in the DBA/2 
mice after switching to the pulmonary route of vaccination, we analyzed T-helper 
17 induction in lungs induced by vaccination and before challenge. Higher 
frequency (Figure 3A) of PPD-specific IL17A-producing CD4+ T cells was 
observed in the mouse group vaccinated intranasally as compared to the 
parenteral or non-vaccinated groups. IL17A production measured by ELISA 
confirmed intracellular staining results (Figure 3B). Increased IL17Aproduction 
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was also observed in spleen from the intranasal group (Figure 3C), suggesting that 
in this model the pulmonary route of vaccination is immunogenic not only at local 
level in lungs, but also systemically. Concurring with these data, we observed a 
similar IFN induction profile in lungs (Figure 4A, 4B) and spleen (Figure 4C), as 
shown with IL17A.  
BCG-conferred protection correlates with pulmonary IL17A induction post-
challenge 
To investigate whether Th17 response induced by pulmonary vaccination in 
DBA/2 mice correlated with protection in lungs, we measured IL17A production in 
parallel with bacterial load reduction four weeks post-low-dose H37Rv challenge. 
Our results indicated that induction of IL17A-secreting CD4+ T cells after challenge 
was restricted to the intranasal BCG-vaccinated group (Figure 5A left panel). 
Linear regression comparing percentage of IL17A+ CD4+ T cells and bacterial load 
in lungs (Figure 5A right panel) indicated a significant correlation between 
reduction in lung bacterial burden and Th17 response induction, providing 
evidence that IL17A could mediate BCG-induced protective efficacy by the 
intranasal route.  
Conversely, we observed no differences in percentage of IFN-producing CD4+ T 
cells post-challenge between vaccinated and non-vaccinated animals (Figure 5B 
left panel). Indeed, comparing Th1 induction and lung bacterial load we found a 
weak but significant positive correlation between cytokine production and CFU 
counts (Figure 5B right panel). 
IL17A contributes to protection conferred by intranasal vaccination  
To study the contribution of IL17A production to protection conferred by 
pulmonary vaccine delivery, we neutralized IL17A in intranasally vaccinated 
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animals. As shown in Figure 6A, IL17A blocking with a specific antibody partially 
diminished BCG efficacy conferred by intranasal vaccination, confirming a role of 
this cytokine in protection. IL17A neutralization was confirmed by the substantial 
cytokine reduction produced in lungs after antibody treatment (Figure 6B). 
Residual IL17A production found in the antibody-treated group could explain the 
remaining protection still detected after IL17A neutralization, although IL17A-
independent factors cannot be excluded. In contrast to IL17A, IFN lung 
production was unaffected in the absence of IL17A (Figure 6C). 
We studied whether neutrophil recruitment in lungs was affected by IL17A 
neutralization, as this process had been previously related with Th17 response 
[13]. Intranasal BCG vaccination caused neutrophil infiltration in lungs. 
Interestingly, IL17A inhibition led to a drop of the percentage as well as the 
number of neutrophils. However, total cell infiltration occurred in the two 
intranasal groups regardless of IL17A neutralization, suggesting that this process 
is mediated by IL17A-independent inflammatory events triggered following 
pulmonary vaccination with BCG (Figure 6D). 
IL17A mediates MTB-specific IgA secretion to lung airways 
IgA represents one of the main defence barriers of the mucosal immune system. 
Therefore, we analysed BAL samples to determine the presence of total and MTB-
specific IgA in the lung airways induced eight weeks post-vaccination. Our results 
showed an increment of total and MTB-specific IgA in BAL from intranasally BCG 
vaccinated mice (Figure 7A). Interestingly, following IL17A-neutralization only 
presence of MTB-specific IgA in BAL was significantly diminished, whereas total 
IgA was unaffected by antibody treatment. Provided that pIgR is the receptor 
molecule responsible for the transport of IgA across lung epithelium, we analysed 
12 
whether pIgR expression would be altered upon vaccination. Our data indicated an 
increase of pIgR protein expression in the lungs of intranasally BCG vaccinated 
mice (Figure 7B), which correlated with higher IgA concentration in BAL found in 
these groups. Moreover, our results suggested that pIgR upregulation depended on 
IL17A production, as pIgR protein expression levels were significantly lower in the 
anti-IL17A-treated group as compared to the intranasally immunized untreated 
group. These results suggest that translocation of MTB-specific IgA to respiratory 
airways and increased pIgR expression levels correlates with IL17A-mediated 
protection upon pulmonary BCG immunization in DBA/2 mice. 
 
DISCUSSION 
Pulmonary vaccination with BCG has been previously reported to improve 
protection when compared with parenteral (subcutaneous or intradermal) 
inoculation [25, 27-29]. Nevertheless, experiments showing these results have 
been usually performed in TB resistant mouse strains (C57BL/6 and BALB/c) in 
which parenteral BCG is considered to be protective. In this work, we demonstrate 
for the first time to our knowledge that a change in the route of vaccination from 
parenteral to pulmonary can overcome the absence of protection observed in a 
model where parenteral BCG does not protect, as it occurs in the TB susceptible 
DBA/2 mouse strain. Extrapolation of these data to TB endemic countries, where 
protection conferred by intradermal BCG is limited, suggests that pulmonary BCG 
administration could have an impact against respiratory TB. Nonetheless, our data 
suggest caution when using BCG by the respiratory route due to the inherent 
safety risks associated with dissemination and unspecific inflammation. Intranasal 
BCG vaccination of DBA/2 mice was accompanied by lung inflammatory aggregate 
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formation and neutrophil infiltration, events usually associated with acute 
inflammation and tissue damage (Supplementary Figure 1 and Figure 6C, 
respectively). In agreement with these data, a previous work described that the 
number of pulmonary BCG immunizations is also critical to induce an exacerbated 
damaging inflammatory response [30].  In addition, considerable number of BCG 
bacilli was found in lungs two months post-vaccination (Supplementary Figure 
2), which could entail some safety concerns in immunocompromised individuals. 
Nevertheless, it is important to remark that BCG administration by the aerosol 
route has been already tested in humans as lung cancer immunotherapy approach, 
showing satisfactory safety results [31], indicating that inflammatory events 
caused by pulmonary BCG vaccination are most likely transient and are not 
harmful at long-term. 
Some authors have described a reduced expression of adhesion molecules on the 
surface of circulating lymphocytes from TB susceptible mice including DBA/2, 
which correlates with a poor presence of lymphocytes in lungs after TB infection 
[21, 32]. Therefore, a plausible explanation as to why subcutaneous BCG 
immunization does not protect in DBA/2 mice could be that vaccine-induced 
systemic immune response is unable to efficiently reach the site of infection. 
Intranasal vaccination could eventually overcome these deficiencies leading to 
antigen presentation directly in the lung draining lymph nodes and the subsequent 
local immune response establishment prior to pathogen encounter. Supporting 
this hypothesis, we have shown that intranasal but not subcutaneous BCG 
vaccination triggers robust Th1 and Th17 responses in lungs of DBA/2 mice. Our 
data strongly suggest that Th17 response induction is particularly important for 
protection against TB conferred by pulmonary BCG vaccination, which is in 
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accordance with previous observations made with other TB vaccines [11, 33]. A 
recent report in TB-infected macaques has demonstrated higher presence of IL17-
producing cells in sterile granulomas as compared to non-sterile ones [34]. The 
induction of Th17 response by intranasal but not subcutaneous vaccination could 
be related with the local inflammatory ambient caused by the presence of BCG in 
the lungs, which would likely provide pro-inflammatory cytokines crucial for the 
differentiation of Th17 cells [35]. Contribution of other IL17-expressing cellular 
subsets, as gamma delta T cells or neutrophils [36], should not be discarded as 
potential contributors of vaccine-induced IL17 production, in addition to Th17 
cells. Our data indicate that IL17A neutralization did not totally abrogate BCG 
intranasally-induced protection, suggesting that other factors may possibly be 
implicated. Further work is needed to understand whether IL17A-independent 
pathways (i.e. IFN production, other IL17 family cytokines) are implicated in 
protective efficacy conferred by pulmonary vaccination. 
A previous work by Khader et al. found that vaccination-induced IL17A enhances 
IFN-producing CD4+ T cell recruitment to the lungs, mainly at very early 
timepoints post challenge [26]. Our data are in apparent discordance with these 
results as we found similar IFN production induced by intranasal vaccination 
independently of IL17A (Figure 6C). However, at the time when we measured 
cytokine production (at two months post-vaccination) IFN-producing cells could 
likely have already been recruited to the lungs independently of IL17A. Indeed, 
these authors detected IFN production in lungs in the absence of IL17A at longer 
time points post-challenge. 
Immunoglobulins can be translocated to respiratory tract passively via blood 
leakages, or actively crossing lung epithelium via pIgR interaction, which is specific 
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for IgA and IgM subtypes [37]. IL17A dependence on both MTB-specific IgA 
translocation and pIgR upregulation suggests that specific IgAs are produced 
locally in lung mucosal tissue, where mycobacterial antigens are abundant after 
pulmonary vaccination, and translocated to respiratory airways exclusively via 
pIgR. Conversely, IL17A-independent translocation of total unspecific IgAs, which 
occurs in the absence of pIgR upregulation, likely indicates that in this case it 
arises from blood leakages. Previous works have described that IL17A contributes 
to IgA secretion in gut and airways as well as pIgR expression in lung epithelium 
[17, 38]. However, the link between IL17A with pIgR expression and IgA secretion 
in the context of mucosal TB vaccines was unreported. Both pIgR and IgA knockout 
mice have shown to be defective in controlling mycobacterial replication [16, 19], 
which could suggest a role of IgAs in protection. Nevertheless, our data do not 
discern whether IgA-induction is a causative factor that contributes to 
intranasally-induced BCG protection. 
Even though different works already showed some decades ago the advantages of 
pulmonary vaccination to protect against TB, no significant attempts to translate 
these results to clinic have been made during the last 20 years. However, and 
probably influenced by the failure of intradermal MVA85A vaccine to improve BCG 
protection in clinic [39], in the last few years a new awareness among the TB 
vaccine scientific community has emerged suggesting that elimination of TB will 
not be achieved only with new vaccine candidates, and exploration of novel 
approaches including new routes of immunization is necessary. In this regard, a 
rising and renewed interest in mucosal immunization has appeared among vaccine 
developers, which is demonstrated by the recently published first clinical trial to 
test the MVA85A subunit vaccine delivered by aerosol route [40]. Therefore, 
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elucidation of protective mechanisms triggered by mucosal immunization might be 
highly valuable in the near future for the rational design of new pulmonary 
vaccines, as well as for the identification of specific biomarkers for these vaccines 
that could predict protection against TB. 
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Figure Legends 
Figure 1. BCG subcutaneous vaccination protects C57/BL6 but not DBA/2 
mice against a pulmonary challenge. Groups of six C57/BL6 (A) or DBA/2 (B) 
mice were vaccinated by the subcutaneous route with BCG Danish vaccine 106 CFU. 
At two months post-vaccination, mice were inoculated intranasally with a low dose 
H37Rv challenge (100 CFU), and one month later lung bacterial burden was 
determined. A representative experiment of two independent is shown. Data in the 
graphs are represented as mean ± SEM. Unpaired t-student test was performed to 
calculate statistical significance. * p<0.05; ** p<0.01; *** p<0.001. 
Figure 2. BCG intranasal vaccination protects DBA/2 against a pulmonary 
challenge. Groups of six DBA/2 mice were vaccinated by the subcutaneous (BCG 
sc), intranasal (BCG in) route, or non-vaccinated (NV) with BCG Danish vaccine 106 
CFU. At two months post-vaccination, mice were inoculated intranasally with a low 
dose (100 CFU) (A) or high dose (1000 CFU) (B) H37Rv challenge, and one month 
later bacterial burden in lungs and spleen was determined. A representative 
experiment of two independent is shown. Data in the graphs are represented as 
mean ± SEM. One-way ANOVA test with Bonferroni post analysis was performed to 
calculate statistical significance. (C) For survival experiments, groups of eight 
animals were vaccinated and challenged with a high dose H37Rv challenge two 
months post-vaccination. Animal survival was determined according to pre-
established endpoint criteria approved by ethical committee. Data from one 
experiment are represented in a Kaplan-Meier survival curve and statistical 
significance calculated by a Logrank test. * p<0.05; ** p<0.01; *** p<0.001. 
Figure 3. BCG intranasal vaccination induces a higher Th17 response prior to 
challenge. Groups of six DBA/2 mice were vaccinated by the subcutaneous (BCG 
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sc) or intranasal (BCG in) route, or non-vaccinated (NV) with BCG Danish vaccine 
106 CFU. At two months post-vaccination, a cellular suspension from harvested 
lungs (A, B) or spleen (C) was obtained. Cells were stimulated with PPD as 
described in materials and methods section. CD4+IL17A+ cells frequency in lungs  
was determined by flow cytometry (A). IL17A concentration in lung (B) or spleen 
(C) cell supernatants was measured by ELISA. Pooled data from two independent 
experiments are shown. Data in the graphs are represented as mean ± SEM. One-
way ANOVA test with Bonferroni post analysis was performed to calculate 
statistical significance. * p<0.05; ** p<0.01; *** p<0.001. 
Figure 4. BCG intranasal vaccination induces a higher Th1 response prior to 
challenge. Groups of six DBA/2 mice were vaccinated by the subcutaneous (BCG 
sc) or intranasal (BCG in) route, or non-vaccinated (NV) with BCG Danish vaccine 
106 CFU. At two months post-vaccination, a cellular suspension from harvested 
lungs (A, B) or spleen (C) was obtained. Cells were stimulated with PPD as 
described in materials and methods section. CD4+IFN+ cells frequency in lungs 
was determined by flow cytometry (A). IFN concentration in lung (B) or spleen 
(C) cell supernatants was measured by ELISA. Pooled data from two independent 
experiments are shown. Data in the graphs are represented as mean ± SEM. One-
way ANOVA test with Bonferroni post analysis was performed to calculate 
statistical significance. * p<0.05; ** p<0.01; *** p<0.001. 
Figure 5. Th17 response induced post challenge correlates with a lower 
bacterial load in lungs. Groups of six DBA/2 mice were vaccinated by the 
subcutaneous (BCG sc) or intranasal (BCG in) route, or non-vaccinated (NV) with 
BCG Danish vaccine 106 CFU. A control group of non-vaccinated, non-infected mice 
was also included (NV/NI). At two months post-vaccination, mice were challenged 
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intranasally with a low H37Rv dose (100 CFU), and one month later animals were 
euthanized. Right and left lungs from the same animal were used to determine 
bacterial load and IL17A- (A) or IFN- (B) producing CD4+ cells, respectively. Data 
in left panels correspond to percentage of cytokine-producing cells measured by 
flow cytometry, and are represented as mean ± SEM. One-way ANOVA test with 
Bonferroni post analysis was performed to calculate statistical significance. * 
p<0.05; ** p<0.01; *** p<0.001. Data from lung CFU and cytokine- producing CD4+ 
cells obtained for each mouse were graphically represented (right panels). Linear 
regression was calculated and the p-value obtained in each case is shown in the 
graph. Pooled data from two independent experiments are shown in the figure. 
Figure 6. IL17A neutralization in vivo impairs protection conferred by BCG 
intranasal vaccination. Groups of six DBA/2 mice were vaccinated by the 
subcutaneous (BCG sc) or intranasal (BCG in) route, or non-vaccinated (NV) with 
BCG Danish vaccine 106 CFU. Intranasal vaccinated mice were treated twice a week 
with 500 g of antiIL17A or isotype control inoculated intraperitoneally. (A) At 
two months post-vaccination, mice were challenged intranasally with a low H37Rv 
dose (100 CFU), and one month later lung bacterial burden was determined. (B, C) 
A group of mice was euthanized prior to challenge and IL17A (B) or IFN (C) 
concentration measured in lung cell culture supernatants after PPD stimulation. D, 
total cell number (left panel), % of neutrophils (defined as Ly6G+CD11b+CD11c- 
cells) (mid panel), and number of neutrophils (right panel) were determined in 
lungs prior to challenge. A representative experiment of two independent is 
shown. Data in the graphs are represented as mean ± SEM. One-way ANOVA test 
with Bonferroni post analysis was performed to calculate statistical significance. * 
p<0.05; ** p<0.01; *** p<0.001. 
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Figure 7. BCG intranasal vaccination induces secretion of MTB-specific IgAs 
and pIgR expression in lungs in an IL17A-dependent manner. Groups of six 
DBA/2 mice were vaccinated by the subcutaneous (BCG sc) or intranasal (BCG in) 
route, or non-vaccinated (NV) with BCG Danish vaccine 106 CFU. Intranasal 
vaccinated mice were treated twice a week with 500 g of antiIL17A or isotype 
inoculated intraperitoneally. (A) At two months post-vaccination, animals were 
euthanized and total and MTB-specific IgA levels measured in BAL as described in 
materials and methods section. (B) Expression of pIgR was measured in 10 g of 
lung lysates by western-blotting. Representative data from two mice per group are 
shown in the western-blot. Pooled data from two independent experiments are 
shown in the graphs. Data in the graphs are represented as mean ± SEM.  One-way 
ANOVA tests with Bonferroni post analysis were performed to calculate statistical 
significance. * p<0.05; ** p<0.01; *** p<0.001. 
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